OVELLA® (ocrelizumab) is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults; and primary progressive MS, in adults.

OVELLA is a 2-times a year prescription infusion for adults with relapsing or primary progressive forms of multiple sclerosis. Our concept sought to embody that empowerment and optimism in treatment.

(Brand name changed to OCREVUS®)

Agency: FCB Health

Role: Copy Supervisor